Human Longevity, Inc: $30m injection. Challenges?

Latest articles

UCL gene discovery raises hope of longer human lifespan

New study discovers that a group of genes that play an essential role in building components of our cells can also impact human lifespan. A...

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

UCL gene discovery raises hope of longer human lifespan

New study discovers that a group of genes that play an essential role in building components of our cells can also impact human lifespan. A...

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Click the globe for translations.

Trouble in paradise? Or extra funding for new goals in precision health analytics?

The abrupt press announcement on the Human Longevity, Inc. website was one of the shortest we’ve seen:

Human Longevity, Inc (“HLI”), an innovator in providing data-driven precision health intelligence platform for physicians and patients, today announced a $30 million financing from veteran biotech investment firms and investors. Existing investor Emerging Technology Partners LLC participated in the financing with other new dedicated healthcare investors.

HLI’s statement said it will use the proceeds from this new round to enhance its Health Nucleus intelligence platform, a research and discovery centre in California which is using integrated metrics derived from specialised imaging, whole genome sequencing and other lab tests with machine learning and AI to create a comprehensive standard for measuring your health and performance and increase healthspan.

It has been over a year since the company issued its last press release. Hmm.

A quick look at Glassdoor indicates some staffing issues – we realise this is a blunt research tool, as most satisfaction surveys are more actively used by the disgruntled – however the $30m could well be bridging ahead of a much larger round: according to Crunchbase the previous $220m Series B round was led by Illumina Ventures while this most recent injection has been led by Emerging Technology Partners.

The San Diego based venture was founded by Craig Venter and Peter Diamandis in 2013. The company is an early mover in advanced diagnostic tools and has a data-driven precision health intelligence platform for detecting diseases before they evolve into bigger problems for both doctors and patients.

Health intelligence has grown substantially over recent years, with technology enabling us to gain a deeper understanding of how we can take a proactive, rather than reactive, approach to aging and health. Human Longevity, Inc states this is the beginning of an era of health intelligence based on their new platform targeting healthspan.

Back in 2017 Venter stated, “We have sequencing that’s better than anybody else in the world. We have the most accurate data” [1]. However, with the average prices for assessments ranging from $5,500 to $25,000, their novel approach to preventive medicine may be out of reach for most. [2].

A handful of competitors appear to be racing ahead, including 23AndMe, Cesca Therapeutics and Pieriandx [3]

[1] https://bit.ly/2Q1VJO3
[2] https://bit.ly/2CqEEFJ
[3] https://www.owler.com/company/humanlongevity

Image: Glen Jackson on Unsplash

 

1 COMMENT

Comments are closed.

Salvinija Roznyte
Staff Writer Salvinija Roznyte is a writer and journalist based in London. She graduated in 2018 with a Bachelor's degree majoring in Writing and Journalism with a minor in Film Studies. She is interested in the way modern medical technology changes and shapes our world.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

Altos Labs lands $3 billion to further cellular rejuvenation programming

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming. Altos Labs launched today as a new biotechnology company dedicated to unravelling...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

    Subscribe to our newsletter